Charleston News Online

Benign Prostatic Hyperplasia (BPH) Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

Benign Prostatic Hyperplasia (BPH) Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 29
17:56 2022
Benign Prostatic Hyperplasia (BPH) Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Benign Prostatic Hyperplasia (BPH) Market
DelveInsight’s “Benign prostatic hyperplasia (BPH) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Benign prostatic hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign prostatic hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Benign prostatic hyperplasia (BPH) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Benign prostatic hyperplasia (BPH), historical and forecasted epidemiology as well as the Benign prostatic hyperplasia (BPH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Benign Prostatic Hyperplasia (BPH) Market Report:

  • The prevalence of BPH determined by Lee et al. (2017), from a study conducted by Kristal et al. (2015),   was 18.4%. The age-specific prevalence was 14.2%, 17.6%, and 23.3% for age groups 50–59, 60–64, and ≥65 years, respectively. 
  • Similarly,  Lee et al. (2017), based on more than seven International Prostate Symptom Score (I-PSS), determined the prevalence of BPH in Germany from the study by Berges et al. (2001) as 29.3%.

Key benefits of the Benign Prostatic Hyperplasia (BPH) Market report:

 

  • The report covers the descriptive overview of Benign prostatic hyperplasia (BPH), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the Benign prostatic hyperplasia (BPH) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Benign prostatic hyperplasia (BPH) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Benign prostatic hyperplasia (BPH) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Benign prostatic hyperplasia (BPH) market

 

Got queries? Click here to know more about the Benign Prostatic Hyperplasia (BPH)  Market Landscape

 

Benign Prostatic Hyperplasia (BPH) Overview

Benign prostatic hyperplasia—also called BPH—is a condition in men in which the prostate gland is enlarged and not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction. As the prostate enlarges, the gland presses against and pinches the urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty completely, leaving some urine in the bladder. The narrowing of the urethra and urinary retention—the inability to empty the bladder completely—cause many of the problems associated with benign prostatic hyperplasia

The cause of benign prostatic hyperplasia is not well understood; however, it occurs mainly in older men. Benign prostatic hyperplasia does not develop in men whose testicles were removed before puberty. For this reason, some researchers believe factors related to aging and the testicles may cause benign prostatic hyperplasia. Scientific studies have suggested that benign prostatic hyperplasia may occur because the higher proportion of estrogen within the prostate increases the activity of substances that promote prostate cell growth.Symptoms of benign prostatic hyperplasia most often come from:

a blocked urethra  bladder that is overworked from trying to pass urine through the blockage

Benign Prostatic Hyperplasia (BPH) Epidemiological Insights:

 

  • As per a study conducted by Lim et al. (2017), the histological prevalence of BPH was observed as 8%, 50%, and 80% in the 4th, 6th, and 9th  decades of life, respectively
  • As per the article by Nash et al. (2010), general practitioners in the UK will, on average, each have 50 men on their list between the ages of 60‒80 years who have moderate or severe urinary symptoms related to BPH.
  • A study conducted by Lee et al. (2017), showed that the median point prevalence of BPH was 25.2%. The study also showed that there was an increasing prevalence of lower urinary tract symptoms (LUTS)/BPH with age, with a pooled prevalence of 14.8%, 20.0%, 29.1%, 36.8%, and 38.4% for age groups of 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years, respectively.

Benign Prostatic Hyperplasia (BPH) Epidemiological Segmentation 

  •  Benign Prostatic Hyperplasia (BPH) total prevalent cases
  •  Benign Prostatic Hyperplasia (BPH) total diagnosed and treatable cases
  •  Benign Prostatic Hyperplasia (BPH) age-specific prevalent cases

Benign Prostatic Hyperplasia (BPH) Market Outlook 

The Benign prostatic hyperplasia (BPH) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Benign prostatic hyperplasia (BPH) market trends by analyzing the impact of current Benign prostatic hyperplasia (BPH) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Benign prostatic hyperplasia (BPH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Benign prostatic hyperplasia (BPH) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Benign prostatic hyperplasia (BPH) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @Benign Prostatic Hyperplasia (BPH)  Market Landscape

Benign Prostatic Hyperplasia (BPH) Key Companies  

  • GemVax & KAEL
  • Urovant Sciences
  • Ausio Pharmaceuticals 
  • And others.

Benign Prostatic Hyperplasia (BPH) Therapies 

  • GV1001
  • Vibegron
  • AUS-131 (S-equo) 
  • And many others 

 

Table of Contents

  • Key Insights 
  • Report Introduction 
  • Executive Summary of Benign Prostatic Hyperplasia (BPH)
  • Disease Background and Overview
  • Epidemiology and patient population
  • Benign Prostatic Hyperplasia (BPH)  Emerging Therapies
  • Benign Prostatic Hyperplasia (BPH) Market Outlook
  • Market Access and Reimbursement of Therapies
  • Appendix
  •  Benign Prostatic Hyperplasia (BPH) Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer
  • About DelveInsight

Click here to read more about Benign Prostatic Hyperplasia (BPH) Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About Author

admin

admin

Related Articles